Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐chronic kidney disease (CKD) Registry, 2019‐2020
Authors' conclusion
Prescribing for GDMT was suboptimal and waned quickly in patients with diabetes and CKD. Type of primary health insurance coverage and health system were associated with GDMT prescribing.
Study context
- Population
- Adults ≥18 years with diabetes and CKD, CURE-CKD Registry, 1 January 2019–31 December 2020; mean age 70 ± 14 years, 49.6% women
- Participants
- 39,158 adults
- Outcome
- GDMT prescribing rates (ACE inhibitor/ARB, SGLT2 inhibitor, GLP-1 RA) at baseline and persistent (≥90 days), and predictors of prescribing persistence
Methodological detailsregistry-based
- Registry-based
Main finding
As reported in the abstract
GDMT prescribing rates, baseline and ≥90-day persistent
- Angiotensin converting enzyme (ACE) inhibitor/ARB, baseline
- 70.7%
- ACE inhibitor/ARB, ≥90-day persistent
- 40.4%
- SGLT2 inhibitor, baseline
- 6.0%
- SGLT2 inhibitor, ≥90-day persistent
- 5.0%
- GLP-1 RA, baseline
- 6.8%
- GLP-1 RA, ≥90-day persistent
- 6.3%
Observational data: associations, not effects.
Further findings
Prescription in patients lacking primary commercial health insurance
- ACE inhibitor/ARB, OR
- 0.89 (95% CI 0.84-0.95; p < .001)
- SGLT2 inhibitor, OR
- 0.72 (95% CI 0.64-0.81; p < .001)
- GLP-1 RA, OR
- 0.89 (95% CI 0.80-0.98; p = .02)
Guideline-directed medical therapy (GDMT) prescribing by health system
- GDMT prescribing rates were lower at Providence than UCLA Health
Original publication
Prescription of guideline‐directed medical therapies in patients with diabetes and chronic kidney disease from the CURE‐CKD Registry, 2019‐2020. Diabetes Obes Metab. Published 3 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →